Abstract:EGFR mutations in SCLC were first reported in cases of lung adenocarcinoma which transformed to SCLC after TKI treatment and such mutation was speculated to be a TKI resistance mechanism. Recently case reports and high throughput sequencing in a small number of samples suggested that EGFR mutations do exist in de novo SCLC. But the genetic and clinical characteristics have not been studied in large number of samples. This study aims to conduct a large scale survey of the EGFR mutations among Chinese SCLC patients, and to analyze the genetic and clinical characteristics of such mutations. Mutation status in exon 18-21 of EGFR was assessed by dideoxy-sequencing in 565 SCLC tumors treated in Zhejiang Cancer Hospital, Hangzhou, China from 2009 to 2014 and correlated with clinical parameters. Chi-square tests were used to show the correlation of clinic variables with EGFR mutation. Survival analysis was performed using the Kaplan-Meier method. 40 instances of EGFR mutation are detected in 565 clinical samples. The mutation rate is 7.1%. Besides classic mutations E19 deletion (n=3) and E21 L858R (n=3), the rest of the mutations detected are atypical including E18 (G719D/S, G696R, S695N/D, N700D, I715F, L688F, P694L), E19(K757N, A755V, V742I, E736K, N756Y, E749K, P753L, A755T), E20 (T790M, H773R, S768R/N, R776H/C, G796D, D807N, R803W/Q, Y813C, G810S, A763T, G779D, Q791R, C781Y, N771S), E21(L858V, G874R, K867E). Among the EGFR mutation positive patients, 27.5% (11/40) are non-smokers, higher than the EGFR negative group (16.4%, 86/525). But it is not statistically significant (p=0.129). And EGFR mutation is not correlated with sex (female vs male), age (≥65y vs <65y) or clinical stages (limited stage vs extensive stage). After matching the treatment history of the EGFR mutation positive and negative patients (excluding patients who were not treated, only treated by traditional Chinese medicine or one cycle chemotherapy or biological therapy, treatment unknown), univariate analysis shows that the EGFR mutation positive patients have better overall survival than the EGFR negative group, with medium OS of 24.433m±4.864m vs 14.00m±0.838m respectively (p=0.018). COX regression analysis suggests that limited stage (HR=2.610), <65 years (HR=1.476) and EGFR mutation (HR=0.587, p=0. 0.039) were independently predictive of better OS. Among the de novo SCLC patients diagnosed, there exists a group harboring EGFR mutations, most of which are non-classic mutations. After matching the treatment history of patients, analysis reveals that EGFR mutations are predictive of better OS.

EGFR Mutations in Non-Small Cell Lung Cancer: an Audit from West China Hospital

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

Prevalence and Clinical Profile of EGFR Mutation in Non- Small-Cell Lung Carcinoma Patients in Southwest China.

Ctdna Assessment of EGFR Mutation Status in Chinese Patients with Advanced Non-Small Cell Lung Cancer in Real-World Setting

EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer

Analysis of EGFR Mutation in Chinese Non-Small Cell Lung Cancer Patients

Molecular epidemiology of EGFR mutations in 7,953 non-small cell lung cancer of Chinese ethnicity.

[Mutations in Exon 19 of EGFR Gene in Non-Small Cell Lung Cancer from Chinese Patients].

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

A Prospective Comparison Study on EGFR Mutations by Direct Sequencing and ARMS in Completely Resected Chinese Non-Small Cell Lung Cancer with Adenocarcinoma Histology (ICAN).

Distribution and Clinical Significance of EGFR Mutations in Phase Ⅰ Non-Small-cell Lung Cancer

[Epidermal Growth Factor Receptor Gene Mutations and Clinicopathologic Correlation in 309 Patients with Non-Small Cell Lung Cancer].

Epidemiological Study of HER-2 Mutations among EGFR Wild-Type Lung Adenocarcinoma Patients in China

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

P1.07-024 EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact: Topic: Molecular Changes

[Detection of Epidermal Growth Factor Receptor Mutations in Non-Small-cell Lung Carcinoma by Direct Sequencing and Correlations with Clinicopathological Characteristics and Sample Types].

The Status of Epidermal Growth Factor Receptor (EGFR) Mutations at Exon 19 and 21 in Chinese Patients with NSCLC

Clinical significance of EGFR mutations in non-small cell lung cancer

The Mutation Profile of EGFR in Resectable Chinese Lung Cancer Patients.

[Relationship Between Mutations of Epidermal Growth Factor Receptor Gene and Clinicopathologic Features of Non-Small Cell Lung Cancers].